Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Dexcom (DXCM) Equity Average (2016 - 2025)

Dexcom (DXCM) has disclosed Equity Average for 15 consecutive years, with $2.7 billion as the latest value for Q4 2025.

  • On a quarterly basis, Equity Average rose 34.07% to $2.7 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $2.7 billion, a 34.07% increase, with the full-year FY2025 number at $2.4 billion, up 16.24% from a year prior.
  • Equity Average was $2.7 billion for Q4 2025 at Dexcom, up from $2.6 billion in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $2.7 billion in Q4 2025 to a low of $1.6 billion in Q1 2021.
  • A 5-year average of $2.2 billion and a median of $2.2 billion in 2023 define the central range for Equity Average.
  • Peak YoY movement for Equity Average: soared 75.92% in 2021, then fell 5.88% in 2024.
  • Dexcom's Equity Average stood at $2.1 billion in 2021, then decreased by 5.31% to $2.0 billion in 2022, then increased by 9.61% to $2.2 billion in 2023, then dropped by 5.88% to $2.0 billion in 2024, then soared by 34.07% to $2.7 billion in 2025.
  • Per Business Quant, the three most recent readings for DXCM's Equity Average are $2.7 billion (Q4 2025), $2.6 billion (Q3 2025), and $2.4 billion (Q2 2025).